BioMarin Pharma (BMRN) Misses Q3 EPS by 2c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $63.94 -1.75%
EPS Growth %: +1,016.7%
Financial Fact:
Selling, general and administrative: 118.76M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +1,016.7%
Financial Fact:
Selling, general and administrative: 118.76M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.04), $0.02 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $505.3 million versus the consensus estimate of $516.56 million.
GUIDANCE:
BioMarin Pharma sees 2022 revenue of $2.06-2.16 billion, versus the consensus of $2.12 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $97 at BMO Capital
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
